An initiative of the Colombian government·  Original source

As we all know, epilepsy is not just a health problem, people with epilepsy also have to cope with a wide range of difficulties that affect almost every aspect of their lives. Many of these difficulties are a consequence of misconceptions, prejudice and stigma.

It is estimated that there are 800,000 people with epilepsy in Colombia, but the number of people affected is tenfold, including family members and relatives. Thus it may be said that 20% of the population of Colombia to some degree suffers because of epilepsy.

Since 2010, the Latin American country has had a law against discrimination against people with epilepsy. The aims of the legislation are:

  • To enhance public education on epilepsy, thus decreasing the fear and misconceptions about the disorder in Colombian society.
  • To improve diagnosis and treatment of epilepsy by providing diagnostic facilities and modern antiepileptic medication.
  • To eliminate discrimination and to improve access to education and employment for people with epilepsy, thus addressing the above mentioned difficulties.

Colombia is a world leader in the human rights of people with epilepsy

Due to this innovative law, Colombia is a world leader in the human rights of people with epilepsy. This is the major step forward in bringing people with epilepsy in Colombia “out of the shadows” at last.

Find out more about this law: “Ley 1414 de 2010” published by The Congress of Colombia

Leave a Reply

El usuario que cumplimenta la información requerida en el presente formulario declara estar legitimado para ello y se hace responsable exclusivo de la veracidad e integridad de los datos e información que introduce, exonerando expresamente a MJN NEUROSERVEIS de cualquier responsabilidad que pudiera generarse para esta entidad con ocasión de la información facilitada a través del presente formulario.

Sí, acepto

Save the date

The next Saturday 21st of November at 4 pm, you will be able to know first hand our product: mjn-SERAS.
mjn-SERAS is a healthcare product that sends a warning signal when the risk of epileptic seizures is high, to the affected person and their trusted contacts.

Sign up now!


    mjn-SERAS is a medical device with CE marking according to the European Directive 93/42/EEC and the Royal Decree RD. 1591/2009.
    Contraindications: Do not use the product if you suffer from an infection in the ear canal or if you suffer from a skin lesion in the vicinity of the product's area of influence.
    Considerations: This medical product works with an APP only on Android phones. The results tested are 96% sensitivity and 94% specificity.
    CPSP20103CAT.

    Save the date

    El próximo sábado 21 de noviembre a las 4 de la tarde, podrás conocer de primera mano nuestro producto: mjn-SERAS.
    mjn-SERAS es un producto sanitario que lanza una señal de aviso cuando el riesgo de crisis de epilepsia es elevado, a la persona afectada y a sus contactos de confianza.

    ¡Inscríbete!

      mjn-SERAS es un producto sanitario con marcado CE conforme a la Directiva Europea 93/42/EEC y el Real Decreto RD. 1591/2009.
      Contraindicaciones: No usar el producto en caso de padecer una infección en el canal auditivo o en caso de padecer una lesión cutánea en las proximidades del área de influencia del producto.
      Consideraciones: Este producto sanitario funciona con una APP solo en teléfonos Android. Los resultados testeados son 96% de sensibilidad y 94% de especificidad.
      CPSP20103CAT.